Scarica l'app Stockscreener
48.43
1.04%
-0.51
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
Ex-BMS General Counsel Joins Bausch Health Board - Law360
Oncology Drugs Market Insights, Competitive Landscape, and Forecast Report 2025-2032 | Immunotherapy Leads Growth in Oncology Market Due to Better Precision and Fewer Side Effects - GlobeNewswire Inc.
Bristol Myers’ Top Doctor Exits in Midst of Search for New Hit Drug - Bloomberg
Bristol Myers Squibb Taps AstraZeneca's Star Executive Who Led 150+ Clinical Studies as New CMO - Stock Titan
What drives Bristol Myers Squibb Company Equity Right stock priceAccelerated wealth expansion - PrintWeekIndia
Bristol-Myers Squibb’s New Study: A Potential Game-Changer in Multiple Myeloma Treatment - TipRanks
Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock? - The Globe and Mail
Jim Cramer Praises Lowe's CEO, As For CrowdStrike: 'I'll See You At $1000' - Benzinga
How Bristol Myers Squibb uses AI to validate drugs before they’re even in the lab - Pharma Voice
Jim Cramer on Bristol-Myers: “Never Seen it This Cheap” - Insider Monkey
Dr Reddy's kicks off India big pharma earnings with narrow profit miss - Reuters
Citi Keeps Their Hold Rating on Bristol-Myers Squibb (BMY) - The Globe and Mail
Bristol-Myers Squibb’s Promising CELMoD Pipeline and Revenue Growth Potential: Analyst Buy Rating - TipRanks
Bristol Myers Squibb Company Stock Analysis and ForecastOutstanding stock performance - jammulinksnews.com
Bristol Myers Squibb Application for Psoriatic Arthritis Drug Accepted for Review in Four Regions - PharmTech
Shareholders in Bristol-Myers Squibb (NYSE:BMY) are in the red if they invested three years ago - simplywall.st
What drives Bristol Myers Squibb Company stock priceFree Advanced Stock Screener Access - jammulinksnews.com
What analysts say about Bristol Myers Squibb Company stockExceptional financial outcomes - Autocar Professional
Lobbying Update: $4,780,000 of BRISTOL-MYERS SQUIBB COMPANY lobbying was just disclosed - Quiver Quantitative
Bristol-Myers Squibb Company (BMY): All Or Nothing With A Breakthrough Drug, Says Jim Cramer - MSN
FDA accepts Bristol Myers Squibb’s application for Sotyktu in psoriatic arthritis - Investing.com
FDA accepts Bristol Myers Squibb’s application for Sotyktu in psoriatic arthritis By Investing.com - Investing.com South Africa
FDA Review: Bristol Myers' Sotyktu Could Become First TYK2 Inhibitor for Psoriatic Arthritis - Stock Titan
Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace
Jim Cramer Reflected on These 17 Stocks - Insider Monkey
Bristol Myers Squibb Stock (BMY) Opinions on Phase 3 Trial Results - Quiver Quantitative
What analysts say about Bristol Myers Squibb Company Equity Right stockFree Stock Selection - Autocar Professional
Why Income Investors Are Watching Bristol-Myers Squibb Company (BMY) in 2025 - Insider Monkey
Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial - AOL.com
BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia - insights.citeline.com
Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb (BMY), Sets a $34 PT - Insider Monkey
Pfizer (PFE) and Bristol Myers (BMY) Launch Direct-to-Patient Eliquis Program - Insider Monkey
Bristol Myers drug fails main goal in cancer-linked anemia trial - Reuters
Bristol-Myers Squibb stock holds steady as Reblozyl study misses endpoint - Investing.com
Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia - BioSpace
Bristol Myers' drug fails main goal in cancer-related anemia trial - Reuters
Bristol Myers' drug fails main goal in late-stage trial for cancer-related anemia - Reuters
Bristol Myers late-stage trial for anemia drug fails (BMY) - Seeking Alpha
Bristol Myers Squibb’s Reblozyl misses primary endpoint in myelofibrosis trial By Investing.com - Investing.com South Africa
Bristol Myers Squibb’s Reblozyl misses primary endpoint in myelofibrosis trial - Investing.com
Boomers Get a Big Beautiful Tax Break: 4 Safe Stocks Yielding 5% to Buy Now - 24/7 Wall St.
BMS, Pfizer take DTC route for blood thinner Eliquis - pharmaphorum
13 Cheap Stocks Under $50 to Buy Now - Insider Monkey
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients - Reuters
Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off - Benzinga
Bristol Myers Squibb and Pfizer Launch Online Discount Program for Eliquis Blood Thinner - geneonline.com
Major drugmakers offer big discount on blood thinner Eliquis - Fox Business
Bristol-Myers Squibb: Morgan Stanley highlights catalyst driven idea By Investing.com - Investing.com South Africa
Bristol-Myers Squibb: Morgan Stanley highlights catalyst driven idea - Investing.com
BMS/Pfizer Offer Direct-to-Consumer Option for Eliquis - Managed Healthcare Executive
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients - Reuters
How Bristol Myers Squibb and Pfizer's Direct-to-Patient Eliquis Initiative is Reshaping Anticoagulant Access and Profitability - AInvest
Drugmakers to Sell Popular Blood Thinner Eliquis at 40% Discount - Bloomberg
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option - BioSpace
Bristol Myers, Pfizer Slash Eliquis Price by 40% with New Direct-to-Patient Program for Top Blood Thinner - Stock Titan
BROKERS’ NOTES: Buy Novo Nordisk, sell Bristol Myers Squibb - BusinessLIVE
Will Increased Expenses Affect Bristol Myers' Performance? - The Globe and Mail
Key facts about Nik Jhangiani, Diageo's new interim CEO - Reuters
0.48%
2.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):